Evaluation of neutralizing efficacy of monoclonal antibodies specific for 2009 pandemic H1N1 influenza A virus in vitro and in vivo

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Archives of Virology

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00705-013-1852-yPMID 24057757
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NA Proteins of Influenza A Viruses H1N1/2009, H5N1, and H9N2 Show Differential Effects on Infection Initiation, Virus Release, and Cell-Cell Fusion

  2013cited by this paper
• The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection

  2013cited by this paper
• Immunogenic and protective properties of the first kazakhstan vaccine against pandemic influenza A (H1N1) pdm09 in Ferrets

  2012cited by this paper
• Escape mutants of pandemic influenza A/H1N1 2009 virus: variations in antigenic specificity and receptor affinity of the hemagglutinin.

  2012influential reference
• Whole Genome Characterization, Phylogenetic and Genome Signature Analysis of Human Pandemic H1N1 Virus in Thailand, 2009–2012

  2012cited by this paper
• A distinct lineage of influenza A virus from bats

  2012cited by this paper
• Antibody Pressure by a Human Monoclonal Antibody Targeting the 2009 Pandemic H1N1 Virus Hemagglutinin Drives the Emergence of a Virus with Increased Virulence in Mice

  2012cited by this paper
• Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection

  2011cited by this paper
• Influenza H5 Hemagglutinin DNA Primes the Antibody Response Elicited by the Live Attenuated Influenza A/Vietnam/1203/2004 Vaccine in Ferrets

  2011cited by this paper
• A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin

  2011cited by this paper
• DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

  2011cited by this paper
• Influenza A/H1N1pdm virus in Russian Asia in 2009-2010.

  2011cited by this paper
• Antivirals and resistance: influenza virus.

  2011cited by this paper
• Minor Changes in the Hemagglutinin of Influenza A(H1N1)2009 Virus Alter Its Antigenic Properties

  2011cited by this paper
• Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination

  2010cited by this paper
• Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection.

  2010cited by this paper
• Protection of Mice against Lethal Challenge with 2009 H1N1 Influenza A Virus by 1918-Like and Classical Swine H1N1 Based Vaccines

  2010cited by this paper
• Characterization of Quasispecies of Pandemic 2009 Influenza A Virus (A/H1N1/2009) by De Novo Sequencing Using a Next-Generation DNA Sequencer

  2010cited by this paper
• Genetic and Phylogenetic Analyses of Influenza A H1N1pdm Virus in Buenos Aires, Argentina

  2010cited by this paper
• Genetic Characterization of the Influenza A Pandemic (H1N1) 2009 Virus Isolates from India

  2010cited by this paper
• Predicting the Antigenic Structure of the Pandemic (H1N1) 2009 Influenza Virus Hemagglutinin

  2010cited by this paper
• The Natural Viral Load Profile of Patients With Pandemic 2009 Influenza A(H1N1) and the Effect of Oseltamivir Treatment

  2010cited by this paper
• Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009.

  2009cited by this paper
• The early diversification of influenza A/H1N1pdm

  2009cited by this paper
• Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic Drift

  2009cited by this paper
• Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

  2009cited by this paper
• Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans

  2009cited by this paper
• Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.

  2009cited by this paper
• Emergence of a novel swine-origin influenza A (H1N1) virus in humans.

  2009cited by this paper
• Pre- and Postexposure Use of Human Monoclonal Antibody against H5N1 and H1N1 Influenza Virus in Mice: Viable Alternative to Oseltamivir

  2009cited by this paper
• Characterization of highly pathogenic H5N1 avian influenza viruses isolated from poultry markets in central China.

  2009cited by this paper
• Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic

  2009cited by this paper
• Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.

  2008cited by this paper
• Treatment with convalescent plasma for influenza A (H5N1) infection.

  2007cited by this paper
• Epitope Mapping of the Hemagglutinin Molecule of a Highly Pathogenic H5N1 Influenza Virus by Using Monoclonal Antibodies

  2007cited by this paper
• The growth and potential of human antiviral monoclonal antibody therapeutics

  2007cited by this paper
• Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?

  2006cited by this paper
• Characterization of a Novel Influenza A Virus Hemagglutinin Subtype (H16) Obtained from Black-Headed Gulls

  2005cited by this paper
• Restoration of virulence of escape mutants of H5 and H9 influenza viruses by their readaptation to mice.

  2005cited by this paper
• Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation.

  2005cited by this paper
• Structural Differences among Hemagglutinins of Influenza A Virus Subtypes Are Reflected in Their Antigenic Architecture: Analysis of H9 Escape Mutants

  2004cited by this paper
• Role of IgA versus IgG in the Control of Influenza Viral Infection in the Murine Respiratory Tract1

  2004cited by this paper
• Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants.

  2002cited by this paper
• Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus.

  2001cited by this paper
• The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin.

  2001cited by this paper
• Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region

  2000cited by this paper
• Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.

  2000cited by this paper
• Antibodies for the prevention and treatment of viral diseases.

  2000cited by this paper
• A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro

  1997cited by this paper
• Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice

  1995cited by this paper
• Hemagglutinin mutations related to antigenic variation in H1 swine influenza viruses

  1992cited by this paper
• An antigenic map of the haemagglutinin of the influenza Hong Kong subtype (H3N2), constructed using mouse monoclonal antibodies.

  1984cited by this paper
• The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype).

  1982cited by this paper
• Determination of the number of nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance.

  1980cited by this paper
• A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

  1938cited by this paper

• EVOLVE: A Web Platform for AI-Based Protein Mutation Prediction and Evolutionary Phase Exploration

  2025cites this paper
• Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus

  2024influential citation
• Generation, characterization, and protective ability of mouse monoclonal antibodies against the HA of A (H1N1) influenza virus

  2022influential citation
• Antigenic Drift of the Hemagglutinin from an Influenza A (H1N1) pdm09 Clinical Isolate Increases its Pathogenicity In Vitro

  2021cites this paper
• Protective efficacy of anti-neuraminidase monoclonal antibodies against H7N9 influenza virus infection

  2020cites this paper
• Two genetically diverse H7N7 avian influenza viruses isolated from migratory birds in central China

  2018cites this paper
• In vitro and in vivo evidence of a potential A(H1N1)pdm09 antigenic drift mediated by escape mutations in the haemagglutinin Sa antigenic site.

  2017cites this paper
• Génération d'anticorps monoclonaux neutralisants et dérive antigénique du virus influenza pandémique A(H1N1) 2009

  2016cites this paper
• A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response

  2016cites this paper
• Influenza vaccines and antivirals that target the conserved hemagglutinin stem

  2016cites this paper
• Potential of a novel peptide P16-D from the membrane-proximal external region of human immunodeficiency virus type 1 to enhance retrovirus infection

  2016cites this paper
• Long-Term Immunogenicity of an Inactivated Split-Virion 2009 Pandemic Influenza A H1N1 Virus Vaccine with or without Aluminum Adjuvant in Mice

  2015cites this paper
• Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus.

  2015influential citation
• Epitope mapping of the 2009 pandemic and the A/Brisbane/59/2007 seasonal (H1N1) influenza virus haemagglutinins using mAbs and escape mutants.

  2014cites this paper
• The passive strategy: Increasing the force in the battle against influenza

  2014cites this paper
• Humanized antibody neutralizing 2009 pandemic H1N1 virus

  2014cites this paper